BioLizard, a leader in multi-omics integration and AI-powered biopharma analytics, is pleased to announce the appointment of Dr. Alexander Scheer as Chief Scientific Officer (CSO). Dr. Scheer is a highly respected R&D executive with a track record of advancing therapies from discovery to clinical proof-of-concept, bringing over 25 years of leadership across biotech, pharma, and translational research. His appointment marks a significant step in scaling BioLizard’s scientific strategy and impact across biomarker discovery, precision medicine, and AI-driven therapeutic innovation.
Dr. Scheer has delivered multiple scientific and strategic milestones throughout his career, including:
- Driving oncology and immuno-oncology programs through IND and into clinical development, including biologics and first-in-class small molecules.
- Leading CasInvent Pharma as CEO/CSO, shaping its scientific and corporate strategy and securing strategic partnerships and financing.
- Serving as CSO of Aelin Therapeutics, where he contributed to advancing groundbreaking Pept-in® technology and expanding the pipeline into multiple therapeutic areas.
- CSO at Erytech Pharma, Head of Research at Pierre Fabre, and senior leadership positions at Merck and Serono, overseeing multi-site research organisations and international scientific collaborations.
“We are honoured to welcome Alexander to BioLizard,” said Liesbeth Ceelen, CEO. “His exceptional track record in translational R&D and pipeline development will elevate our multi-omics and AI-driven biomarker platforms. By harnessing his scientific vision, we strengthen our commitment to develop solutions that measurably improve patient outcomes.”
Dr. Scheer commented:
“Joining BioLizard at this pivotal stage of growth is truly exciting. I look forward to collaborating with this talented team to unlock the full power of multi-omics, bioinformatics, and machine learning, transforming biological complexity into actionable insights for customers and patients.”
About BioLizard
BioLizard is a dynamic, customer-centric tech-enabled biopharma services company specialising in multi-omics data integration, advanced analytics, and AI-enabled biological modelling. Serving biotech and pharmaceutical clients, BioLizard delivers end-to-end solutions, from raw data to impactful clinical insights and accelerated pipeline development. Strategic partnerships and a forward-looking mission position BioLizard as an emerging leader in European tech-enabled life sciences innovation.
